Article
Oncology
Malcolm J. Moore, David Goldstein, John Hamm, Arie Figer, Joel R. Hecht, Steven Gallinger, Heather J. Au, Pawel Murawa, David Walde, Robert A. Wolff, Daniel Campos, Robert Lim, Keyue Ding, Gary Clark, Theodora Voskoglou-Nomikos, Mieke Ptasynski, Wendy Parulekar
Summary: Adding the HER1/EGFR-targeted agent erlotinib to gemcitabine significantly improved overall survival and progression-free survival in patients with advanced pancreatic cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Thierry Conroy, Florence Castan, Anthony Lopez, Anthony Turpin, Meher Ben Abdelghani, Alice C. Wei, Emmanuel Mitry, James J. Biagi, Ludovic Evesque, Pascal Artru, Thierry Lecomte, Eric Assenat, Lucile Bauguion, Marc Ychou, Olivier Bouche, Laure Monard, Aurelien Lambert, Pascal Hammel
Summary: The 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.
Article
Oncology
Arathi Mohan, Kent A. Grif, Fulei Wuchu, David B. Zhen, Chandan Kumar-Sinha, Oxana Crysler, David Hsiehchen, Thomas Enzler, Dominique Dippman, Valerie Gunchick, Abhinav Achreja, Olamide Animasahun, Srinadh Choppara, Minal Nenwani, Arul M. Chinnaiyan, Deepak Nagrath, Mark M. Zalupski, Vaibhav Sahai
Summary: This study investigated the effect of the novel inhibitor, Devimistat, in patients with advanced biliary tract cancer. The results showed that Devimistat in combination with Gemcitabine and Cisplatin had a synergistic effect on cells and significantly decreased oxygen consumption rate. In the clinical trial, the combination therapy of Devimistat with Gemcitabine and Cisplatin demonstrated good safety and efficacy.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Rolf D. Issels, Stefan Boeck, Uwe Pelzer, Ulrich Mansmann, Pirus Ghadjar, Lars H. Lindner, Markus Albertsmeier, Martin K. Angele, Michael Schmidt, Yujun Xu, Marcus Bahra, Johann Pratschke, Michael Schoenberg, Wolfgang E. Thasler, Christoph Salat, Oliver J. Stoetzer, Wolfram T. Knoefel, Dirk Graf, Rudiger Wessalowski, Verena Keitel-Anselmino, Alfred Koenigsrainer, Michael Bitzer, Daniel Zips, Michael Bamberg, Rainer Fietkau, Oliver Ott, Maciej Kawecki, Lucian Wyrwicz, Piotr Rutkowski, Markus Rentsch, Juliana Ababei, Peter Reichardt, Marco Rigamonti, Bernhard Weber, Sultan Abdel-Rahman, Katharina Tschoep-Lechner, Karl-Walter Jauch, Christiane J. Bruns, Helmut Oettle, Michael von Bergwelt-Baildon, Volker Heinemann, Jens Werner
Summary: In this randomized controlled trial, the addition of cisplatin to gemcitabine with regional hyperthermia did not significantly improve disease-free survival in resected pancreatic ductal adenocarcinoma, but it showed a difference in post-recurrence survival and a trend for improved overall survival.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Christine S. Walsh, Mitchell Kamrava, Andre Rogatko, Sungjin Kim, Andrew Li, Ilana Cass, Beth Karlan, Bobbie J. Rimel
Summary: The combination of pembrolizumab, cisplatin and gemcitabine did not show additional benefit beyond chemotherapy alone in patients with recurrent platinum-resistant ovarian cancer. The overall response rate was 60%, with a median progression-free survival of 6.2 months and median overall survival of 11.3 months. However, some patients demonstrated exceptional and durable responses to the treatment.
Article
Oncology
David T. Teachey, Meenakshi Devidas, Brent L. Wood, Zhiguo Chen, Robert J. Hayashi, Michelle L. Hermiston, Robert D. Annett, J. Hunter Archer, Barbara L. Asselin, Keith J. August, Steve Y. Cho, Kimberly P. Dunsmore, Brian T. Fisher, Jason L. Freedman, Paul J. Galardy, Paul Harker-Murray, Terzah M. Horton, Alok Jaju, Allison Lam, Yoav H. Messinger, Rodney R. Miles, Maki Okada, Samir Patel, Eric S. Schafer, Tal Schechter, Neelam Singh, Amii C. Steele, Maria Luisa Sulis, Sarah L. Vargas, Stuart S. Winter, Charlotte Wood, Patrick Zweidler-McKay, Catherine M. Bollard, Mignon L. Loh, Stephen P. Hunger, Elizabeth A. Raetz
Summary: The study indicates that the use of proteasome inhibitor bortezomib can significantly improve event-free survival and overall survival in patients with T-LL. Additionally, intensification of systemic therapy allows for a reduction in the proportion of T-ALL patients requiring prophylactic cranial radiation without increasing the risk of relapse.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Stefano Cascinu, Rossana Berardi, Roberto Bianco, Domenico Bilancia, Alberto Zaniboni, Daris Ferrari, Stefania Mosconi, Andrea Spallanzani, Luigi Cavanna, Silvana Leo, Francesca Negri, Giordano D. Beretta, Alberto Sobrero, Maria Banzi, Alberto Morabito, Alessandro Bittoni, Roberta Marciano, Domenica Ferrara, Silvia Noventa, Maria C. Piccirillo, Roberto Labianca, Cristina Mosconi, Andrea Casadei Gardini, Ciro Gallo, Francesco Perrone
Summary: The combination chemotherapy regimen of Nab-paclitaxel and Gemcitabine showed superior efficacy compared to Gemcitabine alone in patients with unresectable locally advanced pancreatic cancer, reducing disease progression rate and distant relapses, and improving progression-free survival. This randomized trial provides evidence supporting the use of combination chemotherapy in this setting.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Xu Yang, Yirui Zhai, Nan Bi, Tao Zhang, Lei Deng, Wenqing Wang, Xin Wang, Dongfu Chen, Zongmei Zhou, Luhua Wang, Jun Liang
Summary: The study investigated the safety and efficacy of nimotuzumab combined with radiotherapy for elderly patients with non-resectable esophageal carcinoma. Results showed that this treatment approach was relatively safe and effective, but further studies are needed to confirm its therapeutic effects.
CHINESE JOURNAL OF CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez-Kozlova, Kevin G. Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Paul Cetnar, Brock O. Neil, Anishka D'Souza, Ronac Mamtani, Christos Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horwitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert M. Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim-Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John Sfakianos, Sumanta K. Pal
Summary: Cystectomy is a commonly used treatment for muscle-invasive bladder cancer, but it has significant impact on patients' lives. This study aimed to evaluate the clinical complete response rate and the predictive value of clinical complete response for survival in patients with muscle-invasive bladder cancer.
Article
Oncology
Chang Gon Kim, Nam Suk Sim, Jeong Eun Kim, Kum -Hee Yun, Young Han Lee, Seung Hyun Kim, Wooyeol Baek, Yoon Dae Han, Sang Kyum Kim, Jee Hung Kim, Yoon Woo Koh, Inkyung Jung, Su-Jin Shin, Sun Young Rha, Jin-Hee Ahn, Hyo Song Kim
Summary: This study evaluated the efficacy and safety of eribulin-gemcitabine combination therapy in liposarcoma and leiomyosarcoma patients. The results showed promising activity and an acceptable safety profile for this combination treatment. Gene expression profiling and pathway enrichment analysis may have predictive value for survival outcome, but further investigation is needed.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Subha Perni, Beverly Moy, Ryan D. Nipp
Summary: The study found disparities in phase 1 versus phase 2/3 trial enrollment, with Black, Hispanic/Latino, and male patients being less likely to enroll in phase 1 trials compared to White patients. The findings suggest a need for targeted interventions to improve access to and education about phase 1 trials for Black and Hispanic/Latino patients.
Article
Oncology
Q. P. Janssen, J. L. van Dam, B. A. Bonsing, H. Bos, K. P. Bosscha, P. P. L. O. Coene, C. H. J. van Eijck, I. H. J. T. de Hingh, T. M. Karsten, M. B. van der Kolk, G. A. Patijn, M. S. L. Liem, H. C. van Santvoort, O. J. L. Loosveld, J. De Vos-Geelen, B. M. Zonderhuis, M. Y. Homs, G. van Tienhoven, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp
Summary: The PREOPANC-2 trial compares two neoadjuvant regimens for patients with resectable and borderline resectable pancreatic cancer, aiming to provide evidence for the optimal neoadjuvant treatment choice in these patients.
Article
Oncology
Shouki Bazarbashi, Mahmoud A. Elshenawy, Ahmed Badran, Ali Aljubran, Ahmed Alzahrani, Hadeel Almanea, Abdullah Alsuhaibani, Ahmed Alashwah, Mohamed Neimatallah, Alaa Abduljabbar, Luai Ashari, Samar Alhomoud, Hazem Ghebeh, Tusneem Elhassan, Nasser Alsanea, Mohammed Mohiuddin
Summary: The efficacy and toxicity of preoperative concurrent infusional gemcitabine and radiotherapy in locally advanced rectal cancer were tested in this study. The results showed that this treatment achieved an encouraging degree of local control with manageable toxicity.
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Oncology
Steven Attia, Victor Villalobos, Nadia Hindi, Andrew J. Wagner, Bartosz Chmielowski, Gerard J. Oakley, Patrick M. Peterson, Matteo Ceccarelli, Robin L. Jones, Mark A. Dickson
Summary: Gemcitabine plus docetaxel is an effective treatment for soft tissue sarcomas. However, the prognosis for patients remains poor, emphasizing the need for novel therapies. The ANNOUNCE 2 trial explored the addition of olaratumab to the treatment regimen for advanced STS. The study found no significant difference in overall survival between the investigational and control arms.
Article
Oncology
Peter J. Hurley, Nandita Bose, Gautam Jha, Michele Gargano, Nadine Ottoson, Keith Gorden, Blaine Rathmann, Ben Harrison, Xiaohong Qiu, Arkadiusz Z. Dudek
ANTICANCER RESEARCH
(2020)
Article
Oncology
Arkadiusz Z. Dudek, Li C. Liu, Shilpa Gupta, Theodore F. Logan, Eric A. Singer, Monika Joshi, Yousef N. Zakharia, Joshua M. Lang, James K. Schwarz, Anas Al-Janadi, Ajjai S. Alva
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Oncology
R. D. Carvajal, J. S. Weber, A. Z. Dudek, J. Grewal, I. Mehmi, O. Hamid, Y. Du, M. Desai, Y. Wang, L. Sun, J. Rege, M. R. Middleton
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Erlene Kuizon Seymour, Jordi Rodon Ahnert, Bingxia Wang, Dennis Huszar, Allison J. Berger, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim, Anthony J. Olszanski
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Manish Patel, Shanda H. Blackmon, Arkadiusz Z. Dudek, Naomi Fujioka, Shirley Kern, Nancy Torrison, Pasi A. Janne
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Dylan M. Zylla, Justin Eklund, Grace Gilmore, Alissa Gavenda, Jordan Guggisberg, Gabriela VazquezBenitez, Pamala A. Pawloski, Tom Arneson, Sara Richter, Angela K. Birnbaum, Stephen Dahmer, Matthew Tracy, Arkadiusz Dudek
Summary: The study aimed to investigate the impact of using medical cannabis on pain control in cancer patients. The results showed that patients in the early cannabis group performed better in reducing opioid use and improving pain control, with high satisfaction reported by patients.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Biochemistry & Molecular Biology
Patrick M. Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N. Smith, Archana Balan, James R. White, Christopher Cherry, I. K. Ashok Sivakumar, Xiaoshan M. Shao, Hok Yee Chan, Dipika Singh, Sampriti Thapa, Peter B. Illei, Drew M. Pardoll, Rachel Karchin, Victor E. Velculescu, Julie R. Brahmer, Suresh S. Ramalingam
Summary: The combination of durvalumab with platinum-based chemotherapy shows promising clinical activity in patients with malignant pleural mesothelioma, leading to improved survival rates. Adverse events during treatment were in line with known side effects of chemotherapy, and immunotherapy-induced adverse reactions were mild.
Meeting Abstract
Oncology
Arkadiusz Dudek, Dejan Juric, Afshin Dowlati, Ulka Vaishampayan, Hadeel Assad, Jordi Rodon, Bo Chao, Bingxia Wang, John Gibbs, Vaishali Shinde, Sharon Friedlander, Allison Berger, Christine Ward, Alonzo Martinez, Robert Gharavi, Alejandro Gomez-Pinillos, Igor Proscurshim, Anthony Olszanski
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Melissa Johnson, Arkadiusz Z. Dudek, Ammar Sukari, Justin Call, Paul R. Kunk, Karl Lewis, Justin F. Gainor, John Sarantopoulos, Patrice Lee, Adele Golden, Allison Harney, S. Michael Rothenberg, Yuanyuan Zhang, Jonathan W. Goldman
Summary: This study evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors. The results showed limited clinical benefit, but the combination therapy was well tolerated.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, Research & Experimental
Zhihui Xie, Magne Borset, Kjell Sveen, Ole Wilhelm Boe, Eunice C. Chan, Justin B. Lack, Katherine M. Hornick, Franco Verlicchi, A. Robin Eisch, Remo Melchio, Arkadiusz Z. Dudek, Kirk M. Druey
Summary: This study found that dysfunction of eGCX may contribute to clinical symptoms of acute ISCLS, while endothelial cell injury is not significant. There is a significant difference in the abundance of eGCX-related proteins in plasma between acute and remission phase of ISCLS. Measurement of eGCX components during acute episodes of ISCLS can be used to monitor clinical status and therapeutic responses.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele
Summary: The study found that TKI-resistant ROS1+ NSCLC cells displayed MET amplification without activating mutations. MET amplification was also observed in patient samples receiving ROS1 TKI therapy. This suggests that MET-mediated resistance may occur following treatment with ROS1-selective inhibitors.
Article
Oncology
Oana C. C. Danciu, Matthias Holdhoff, Richard A. A. Peterson, James H. H. Fischer, Li C. C. Liu, Heng Wang, Neeta K. K. Venepalli, Rozina Chowdhery, M. Kelly Nicholas, Meredith J. J. Russell, Timothy M. M. Fan, Paul J. J. Hergenrother, Theodore M. M. Tarasow, Arkadiusz Z. Z. Dudek
Summary: This study is the first-in-human clinical trial of PAC-1, assessing its maximum tolerated dose, safety, and pharmacokinetics. The recommended phase 2 dose of PAC-1 was found to be 750 mg/day. The study also observed clinical activity of PAC-1 in patients with neuroendocrine tumors, suggesting further investigation is warranted.
BRITISH JOURNAL OF CANCER
(2023)
Meeting Abstract
Oncology
G. Saggu, D. Stroopinsky, A. Z. Dudek, A. J. Olszanski, D. Juric, A. Dowlati, U. Vaishampayan, H. Assad, J. Rodon, J. Gibbs, J. Green, Z. Du, R. Rudicell, K. Kannan, R. Gharavi, A. Gomez-Pinillos, R. J. Fram, A. Berger, K. Sachsenmeier, S. Kasar
EUROPEAN JOURNAL OF CANCER
(2022)
Meeting Abstract
Oncology
Jeffrey S. Weber, Richard D. Carvajal, Omid Hamid, Seung Tae Kim, Miso Kim, Ryan J. Sullivan, Dae Ho Lee, Inderjit Mehmi, Jaspreet Singh Grewal, Hyo Jin Lee, Arkadiusz Z. Dudek, Yangchun Du, Monali Desai, Yan Wang, Carlos Alberto Mayo, Mark R. Middleton
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Ruth O'Regan, Randolph Hurley, Jasgit Sachdev, Jonathan Bleeker, Debra Tonetti, Gregory Thatcher, Robert Venuti, Arkadiusz Dudek